Nivolumab
Brand name: Opdivo
Rank #462 of 500 drugs by total cost
$16.0M
Total Cost
1,275
Total Claims
$16.0M
Total Cost
51
Prescribers
$13K
Cost per Claim
63
Beneficiaries
1,280
30-Day Fills
$314K
Avg Cost/Provider
25
Avg Claims/Provider
About Nivolumab
Nivolumab (sold as Opdivo) was prescribed 1,275 times by 51 Medicare Part D providers in 2023, costing the program $16.0M. At $13K per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 459 | Telmisartan (Telmisartan) | $16.4M | 334,601 |
| 460 | Letermovir (Prevymis) | $16.1M | 2,144 |
| 461 | Fluphenazine Hcl (Fluphenazine Hcl) | $16.0M | 73,051 |
| 462 | Nivolumab (Opdivo) | $16.0M | 1,275 |
| 463 | Leflunomide (Leflunomide) | $16.0M | 205,765 |
| 464 | Hydrocortisone (Hydrocortisone) | $15.9M | 762,398 |
| 465 | Digoxin (Digoxin) | $15.9M | 548,410 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology